ArticleBritish journal of clinical pharmacology2022

Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.

Rebecca C Furze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.